Cellular Biomedicine Group Inc (NASDAQ:CBMG) – B. Riley issued their Q1 2018 earnings per share estimates for Cellular Biomedicine Group in a research note issued to investors on Thursday. B. Riley analyst G. Zavoico anticipates that the biotechnology company will post earnings per share of ($0.47) for the quarter. B. Riley has a “Buy” rating and a $32.00 price target on the stock. B. Riley also issued estimates for Cellular Biomedicine Group’s Q2 2018 earnings at ($0.47) EPS, Q3 2018 earnings at ($0.49) EPS, Q4 2018 earnings at ($0.51) EPS, FY2018 earnings at ($1.94) EPS, FY2019 earnings at ($1.96) EPS, FY2020 earnings at ($1.92) EPS, FY2021 earnings at $1.22 EPS and FY2022 earnings at $10.43 EPS.

How to Become a New Pot Stock Millionaire

A number of other research firms also recently commented on CBMG. BidaskClub upgraded Cellular Biomedicine Group from a “hold” rating to a “buy” rating in a report on Wednesday, January 10th. Maxim Group downgraded Cellular Biomedicine Group from a “buy” rating to a “hold” rating in a report on Thursday, February 1st.

Cellular Biomedicine Group (CBMG) opened at $19.75 on Monday. Cellular Biomedicine Group has a 1-year low of $5.05 and a 1-year high of $22.75.

Cellular Biomedicine Group (NASDAQ:CBMG) last issued its quarterly earnings results on Tuesday, March 6th. The biotechnology company reported ($0.48) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.40) by ($0.08). Cellular Biomedicine Group had a negative return on equity of 45.60% and a negative net margin of 7,564.10%. The company had revenue of $0.07 million for the quarter.

In other Cellular Biomedicine Group news, insider Yihong Yao acquired 4,167 shares of the company’s stock in a transaction dated Friday, December 22nd. The shares were acquired at an average price of $12.00 per share, for a total transaction of $50,004.00. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, SVP Andrew K. Chan acquired 8,333 shares of the company’s stock in a transaction dated Friday, December 22nd. The stock was acquired at an average price of $12.00 per share, for a total transaction of $99,996.00. The disclosure for this purchase can be found here. In the last quarter, insiders bought 41,667 shares of company stock worth $500,004. Company insiders own 8.20% of the company’s stock.

An institutional investor recently bought a new position in Cellular Biomedicine Group stock. Goldman Sachs Group Inc. acquired a new stake in Cellular Biomedicine Group Inc (NASDAQ:CBMG) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 61,733 shares of the biotechnology company’s stock, valued at approximately $540,000. Goldman Sachs Group Inc. owned about 0.43% of Cellular Biomedicine Group as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 2.79% of the company’s stock.

WARNING: “Cellular Biomedicine Group Inc (CBMG) Forecasted to Earn Q1 2018 Earnings of ($0.47) Per Share” was originally reported by Daily Political and is owned by of Daily Political. If you are viewing this news story on another website, it was stolen and republished in violation of US & international copyright & trademark laws. The correct version of this news story can be accessed at https://www.dailypolitical.com/2018/03/14/cellular-biomedicine-group-inc-cbmg-forecasted-to-earn-q1-2018-earnings-of-0-47-per-share.html.

Cellular Biomedicine Group Company Profile

Cellular Biomedicine Group Inc is a United States-based company which is engaged in the development of cell therapy technologies. The Company develops proprietary cell therapies for the treatment of cancer and degenerative diseases. The Company conducts immuno-oncology and stem cell clinical trials in China using products from the good manufacturing practices (GMP) laboratory.

Receive News & Ratings for Cellular Biomedicine Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellular Biomedicine Group and related companies with MarketBeat.com's FREE daily email newsletter.